Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.45 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31614317 | 1.00 | SLC7A5 (0.60) | SLC7A5LOXL2FOLH1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL8123098 | 0.97 | SLC7A5 (0.60) | SLC7A5LOXL2FOLH1CYP4F2CYP4A11 | |
| Bromide SCHEMBL5228525 | 0.93 | SLC7A5 (0.56) | SLC7A5LOXL2FOLH1CYP4F2CYP4A11 | |
| Bromide SCHEMBL7025256 | 0.86 | CYP4F2 (0.56) | SLC7A5CYP4F2CYP4A11ALDH1A1SNCA | |
| SCHEMBL10484536 | 0.86 | SLC7A5 (0.49) | SLC7A5LOXL2FOLH1CYP4F2CYP4A11 | |
| Bromide SCHEMBL9546910 | 0.85 | SNCA (0.55) | SLC7A5LOXL2ALDH1A1HPGDTSHR | |
| SCHEMBL10484454 | 0.85 | MAPT (0.51) | SLC7A5LOXL2FOLH1CYP4F2CYP4A11 | |
| Bromide SCHEMBL197541 | 0.84 | SNCA (0.61) | LOXL2CYP4F2CYP4A11ALDH1A1HPGD | |
| Bromide SCHEMBL972872 | 0.83 | FOLH1 (0.56) | FOLH1SNCA | |
| Hydrochloric Acid SCHEMBL9493443 | 0.82 | CA1 (0.54) | SLC7A5LOXL2ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186543-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20220331397-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2022-10-20 | — | — | US | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| EP-3458470-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2695881-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-3002278-A1 | GUANIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-4474804-A | 7-Oxabicyclo substituted prostaglandin phenyl carboxylic acid derivatives useful as cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0080061-A1 | Cis-bicyclo(3.3.0)octane derivatives, medicines containing them and process for the preparation of these compounds and these medicines | Grünenthal GmbH (DE) | 1983-06-01 | — | — | EP | disclosed |
| US-4356292-A | FROM ACID CHLORIDE OF BIS-M-CARBOXYPHENYLACETYLENE, DIPHENYL ETHER, ISOPHTHALOYL CHLORIDE, 4,4'-DIPHENOXYDIPHENYL SULFONE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1982-10-26 | — | — | US | disclosed |
| EP-0001900-B1 | 9-THIA-12-AZAPROSTANOIC ACID DERIVATIVES AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1982-04-07 | — | — | EP | disclosed |
| US-4260771-A | VASODILATORS, ANTICOAGULANTS, IMMUNOLOGY | MERCK & CO., INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4225609-A | Interphenylene 9-thia-11-oxo-12-aza-prostanoic acids | MERCK & CO., INC. (US) | 1980-09-30 | — | — | US | disclosed |
| US-4175203-A | TREATMENT OF RENAL FAILURE AND TRANSPLANT REJECTION VASODILATORS | MERCK & CO., INC. (US) | 1979-11-20 | — | — | US | disclosed |
| EP-0001900-A1 | 9-Thia-12-azaprostanoic acid derivatives and compositions containing them | MERCK & CO. INC. (US) | 1979-05-16 | — | — | EP | disclosed |
| US-4150235-A | ANTIBODY INHIBITORS, HYPOTENSIVE AGENTS, DIURETICS, VASODILATOR | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| US-4140861-A | RENAL DISFUNCTION, ANTIBODY INHIBITORS | MERCK & CO., INC. (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186543-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MTPN, MYLK2 | SLC7A5 2234/4885LOXL2 3005/4885FOLH1 4057/4885 |
| US-20220331397-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MTPN, MYLK2 | SLC7A5 2234/4885LOXL2 3005/4885FOLH1 4057/4885 |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | SLC7A5 2750/4885LOXL2 3183/4885FOLH1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.